TY - JOUR
T1 - [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice
AU - Wong-Sefidan, Ida
AU - Byrtek, Michelle
AU - Zhou, Xiaolei
AU - Friedberg, Jonathan W.
AU - Flowers, Christopher R.
AU - Zelenetz, Andrew D.
AU - Dawson, Keith L.
AU - Reid, Erin
N1 - Publisher Copyright:
© 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/4/3
Y1 - 2017/4/3
N2 - Positron emission tomography (PET) after induction therapy in follicular lymphoma (FL) is predictive of survival in clinical trials. We describe use of PET and computed tomography (CT) after rituximab-based induction therapy in FL patients followed by the National LymphoCare Study and explore the association between imaging response assessment and survival. Among 1289 patients, imaging consisted of: PET ± CT (35%), CT alone (42%), other/no imaging (24%). Median follow-up was 7.6 years. In unadjusted analyses, positive PET ± CT and CT were prognostic of inferior OS (HR 1.78; 95% CI: 1.16–2.72 and HR 1.61, 95% CI: 1.13–2.29, respectively) and PFS (HR 1.63, 95% CI: 1.21–2.20 and HR 1.45, 95% CI: 1.12–1.89, respectively). Adjusting for FL International Prognostic Index, PET remained predictive of OS (HR 1.54, 95% CI: 1.01–2.36) and PFS (HR 1.54, 95% CI: 1.14–2.07). Residual disease via PET in FL is prognostic of survival in clinical practice.
AB - Positron emission tomography (PET) after induction therapy in follicular lymphoma (FL) is predictive of survival in clinical trials. We describe use of PET and computed tomography (CT) after rituximab-based induction therapy in FL patients followed by the National LymphoCare Study and explore the association between imaging response assessment and survival. Among 1289 patients, imaging consisted of: PET ± CT (35%), CT alone (42%), other/no imaging (24%). Median follow-up was 7.6 years. In unadjusted analyses, positive PET ± CT and CT were prognostic of inferior OS (HR 1.78; 95% CI: 1.16–2.72 and HR 1.61, 95% CI: 1.13–2.29, respectively) and PFS (HR 1.63, 95% CI: 1.21–2.20 and HR 1.45, 95% CI: 1.12–1.89, respectively). Adjusting for FL International Prognostic Index, PET remained predictive of OS (HR 1.54, 95% CI: 1.01–2.36) and PFS (HR 1.54, 95% CI: 1.14–2.07). Residual disease via PET in FL is prognostic of survival in clinical practice.
KW - Follicular lymphoma
KW - PET
KW - prognostic
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=84981731030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981731030&partnerID=8YFLogxK
U2 - 10.1080/10428194.2016.1213824
DO - 10.1080/10428194.2016.1213824
M3 - Article
C2 - 27562750
AN - SCOPUS:84981731030
SN - 1042-8194
VL - 58
SP - 809
EP - 815
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -